CD14 and cancer: For flow cytometry based assays, reporting the abundance of CD14+HLA-DRlo/neg monocytes as a percent of PBMCs or total leukocytes is the least informative, particularly when measuring these cells from cancer patients where many patients exhibit severe leukopenia and/or lymphopenia.